Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Simple item page
dc.contributor.authorLee, Oi Lin
dc.contributor.authorHorvath, N.
dc.contributor.authorLee, Cindy
dc.contributor.authorJoshua, D.
dc.contributor.authorHo, J.
dc.contributor.authorSzer, Jeff
dc.contributor.authorQuach, H.
dc.contributor.authorSpencer, Andrew
dc.contributor.authorMollee, P.
dc.contributor.authorRoberts, Andrew A.
dc.contributor.authorTalaulikar, Dipti
dc.contributor.authorJohnston, Anna M.
dc.date.accessioned2020-12-20T20:51:46Z
dc.date.available2020-12-20T20:51:46Z
dc.date.issued2017
dc.date.updated2020-11-23T10:15:35Z
dc.description.abstractMultiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal-related events such as pathologic fracture, spinal cord compression and hypercalcaemia. MBD is the result of MM plasma cells-mediated activation of osteoclast activity and suppression of osteoblast activity. Bisphosphonates (BP), pyrophosphate analogues with high bone affinity, are the only pharmacological agents currently recommended for the treatment and prevention of MBD and remain the standard of care. Pamidronate and zoledronic acid are the most commonly used BP to treat MBD. Although generally safe, frequent high doses of BP are associated with adverse events such as renal toxicity and osteonecrosis of the jaw. As such, optimal duration and dosing of BP therapy is required in order to minimise BP-associated adverse events. The following guidelines provide currently available evidence for the adoption of a tailored approach when using BP for the management of MBD.
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1444-0903
dc.identifier.urihttp://hdl.handle.net/1885/217879
dc.language.isoen_AUen_AU
dc.publisherBlackwell Science Asia
dc.sourceInternal Medicine Journal
dc.titleBisphosphonate guidelines for treatment and prevention of myeloma bone disease
dc.typeJournal article
dcterms.accessRightsFree Access via Publisher Site
local.bibliographicCitation.issue8
local.bibliographicCitation.lastpage951
local.bibliographicCitation.startpage938
local.contributor.affiliationLee, Oi Lin, Royal Adelaide Hospital
local.contributor.affiliationHorvath, N., Department of Haematology
local.contributor.affiliationLee, Cindy, Medical and Scientific Advisory Group
local.contributor.affiliationJoshua, D, University of Sydney
local.contributor.affiliationHo, J, University of Sydney
local.contributor.affiliationSzer, Jeff, Royal Melbourne Hospital
local.contributor.affiliationQuach, H, The University of Melbourne
local.contributor.affiliationSpencer, Andrew, The Alfred Hospital
local.contributor.affiliationMollee, P, Princess Alexandra Hospital
local.contributor.affiliationRoberts, Andrew A, Walter and Eliza Hall Institute of Medical Research
local.contributor.affiliationTalaulikar, Dipti, College of Health and Medicine, ANU
local.contributor.affiliationJohnston, Anna M., Royal Hobart Hospital
local.contributor.authoremailu4283279@anu.edu.au
local.contributor.authoruidTalaulikar, Dipti, u4283279
local.description.embargo2099-12-31
local.description.notesImported from ARIES
local.identifier.absfor111299 - Oncology and Carcinogenesis not elsewhere classified
local.identifier.ariespublicationa383154xPUB8210
local.identifier.citationvolume47
local.identifier.doi10.1111/imj.13502
local.identifier.scopusID2-s2.0-85026842647
local.identifier.thomsonID000407229400015
local.identifier.uidSubmittedBya383154
local.type.statusPublished Version

Downloads

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Internal Medicine Journal - 2017 - Lee - Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.pdf
Size:
528.21 KB
Format:
Adobe Portable Document Format
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2024 LYRASIS